Cargando…
Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update
The prevalence of metabolic (dysfunction)-associated fatty liver disease (MAFLD) is rapidly increasing and affects up to two billion individuals globally, and this has also resulted in increased risks for cirrhosis, hepatocellular carcinoma, and liver transplants. In addition, it has also been linke...
Autores principales: | Alharthi, Jawaher, Eslam, Mohammed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
XIA & HE Publishing Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845164/ https://www.ncbi.nlm.nih.gov/pubmed/35233382 http://dx.doi.org/10.14218/JCTH.2021.00248 |
Ejemplares similares
-
Macrophages in metabolic associated fatty liver disease
por: Alharthi, Jawaher, et al.
Publicado: (2020) -
Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
por: Barchetta, Ilaria, et al.
Publicado: (2020) -
Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
por: Sangro, Paloma, et al.
Publicado: (2023) -
A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes
por: Alharthi, Jawaher, et al.
Publicado: (2022) -
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
por: Shi, Yiwen, et al.
Publicado: (2022)